Figure 4 from Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)

Abstract

<p>Association of biomarkers of interest with clinical outcomes by treatment group in chemotherapy-naïve patients. <b>A,</b> Changes in transcriptional DDR features between primary and recurrent disease. <i>P</i> values presented from <i>t</i> tests comparing primary and recurrent scores in paired samples. PT, primary tumor; REC, recurrent tumor. <b>B,</b> Association of biomarkers with objective response in chemotherapy-naïve patients. Odds ratios for each biomarker are presented from univariable logistic regression models. Stars indicate that an odds ratio could not be estimated due to colinearity (i.e., a cutoff could perfectly separate responders from nonresponders). <b>C,</b> Biomarker by response in chemotherapy-naïve, carboplatin-treated patients for biomarkers where a model could not be fitted due to a perfect cutoff between responders and nonresponders. <b>D,</b> Association of biomarkers with PFS in chemotherapy-naïve patients. Model coefficients of each biomarker are presented from linear regression of restricted mean PFS. Ninety-five percent confidence intervals are shown.</p>